undamentalytics Newsletter
Sign in

Taysha Gene Therapies, Inc. balance sheet

At the end of fiscal 2025, Taysha Gene Therapies, Inc. had total assets of $343m, total liabilities of $96.4m and shareholders' equity of $247m. It held $320m in cash against $50.1m of debt: net cash of $270m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents88144139320455
Total current assets96150142325461
Total assets126173160343470
Accounts payable116469
Deferred revenue (current)341810——
Total current liabilities6337262726
Long-term debt3841445049
Total debt4041445050
Total liabilities12598899683
Shareholders' equity17572247387
Net debt (negative = net cash)−48−103−95−270−405
Shares outstanding——205m285m325m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: IMRN vs TSHAIVA vs TSHAANL vs TSHACGON vs TSHA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Taysha Gene Therapies, Inc.